İnsomnia hastalarında serum triptofan-kinürenin yolağı metabolit düzeylerinin araştırılması
Yükleniyor...
Dosyalar
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Selçuk Üniversitesi, Sağlık Bilimleri Enstitüsü
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmadaki amacımız insomnia hastalarının triptofan-kinürenin yolağı üzerindeki etkisini değerlendirmektir. İnsomnia hastalarında PUKİ ve ISI ölçekleri çalışmaya dahil edimiş ve triptofan-kinürenin metabolitleri arasındaki ilişki çalışma kapsamıda incelenmiştir. Çalışmaya Selçuk Üniversitesi Tıp Fakültesi Hastanesi Psikiyatri polikliniğine başvuran 18-65 yaş aralığında insomnia tanısı almış olan 30 hasta ve sağlıklı 30 kontrol dahil edilmiştir. Katılımcıların serum örneklerinden triptofan, kinürein, kinürenik asit, 3-OH kinürenin, 3-OH antranilik asit ve kinolinik asit düzeylerinin analizi için rutin biyokimya laboratuvarımızda bulunan LC-MS/MS (tandem kütle spektrometresi) cihazında kurulu olan yöntemlerin linearite çalışması yapılarak yöntem verifikasyonu sağlanmış olup düzeyleri ölçülmüştür. Elde edilen veriler SPSS 21.0 programı kullanılarak gerçekleştirildi. Bulduğumuz sonuçlara göre PUKİ ve ISI değerleri hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulunmuştur (sırasıyla p=0,001 ve p=0,001). KYN ve KUIN hasta grubunda kontrol grubuna göre istatiksel olarak anlamlı derecede yüksekken (sırasıyla p<0,001ve p<0,001) TRP, KYNA ve 3-HK hasta grubu kontrol grubuna kıyasla düşük gözlemlenmiştir (sırasıyla p=0,001, p<0,001 ve p=0,002). 3-HAA için hasta ve kontrol grubu arasında anlamlı bir fark bulunamamıştır (p=0,464). Çalışmamızda Spearman korelasyon analizi kullanmış olup yaş ve PUKİ ile yaş ve ISI arasında negatif korelasyon saptanmıştır. PUKİ ve ISI arasında ise pozitif bir korelasyon bulunmaktadır. İnsomnia hastalığında triptofan-kinürenin metabolitleri anlamlı düzeyde farklılık vardır. Elde ettiğimiz veriler, triptofan-kinürein yolağı metabolitlerinin hastalığın prognozunda biyobelirteç olarak kullanılabileceği düşünülmektedir. İnsomnia hastalığında rol alan moleküller ve biyokimyasal mekanizmaların anlaşılması, hastalık için yeni etkili ve güvenli tedavilerin geliştirilmesine katkı sağlayacağı düşünülmektedir.
Our aim in this study is to evaluate the capacity of insomnia patients on the tryptophan-kynurenine pathway. PSQI and ISI scale studies in insomnia patients were included and the relationship between tryptophan-kynurenine metabolites was separated within the scope of the study. The study included 30 patients diagnosed with insomnia between the ages of 18-65 who applied to the Psychiatry outpatient clinic of Selçuk University Faculty of Medicine Hospital and 30 healthy controls. Method verification was provided by conducting a linearity study of the methods installed on the LC-MS/MS (tandem mass spectrometry) device in our routine biochemistry laboratory for the analysis of tryptophan, kynureine, kynurenic acid, 3-OH kynurenine, 3-OH anthranilic acid and quinolic acid levels in the serum samples of the participants. And their levels were measured. The data obtained was carried out using the SPSS 21.0 program. According to the results of our study, PSQI and ISI values were found to be significantly higher in the patient group than in the control group (p=0.001 and p=0.001, respectively). While KYN and KUIN were statistically significantly higher in the patient group than in the control group (p<0.001 and p<0.001, respectively), TRP, KYNA and 3-HK were observed to be lower in the patient group compared to the control group (p=0.001, p<0.001 and p=0.002, respectively). No significant difference was found between the patient and control groups for 3-HAA (p = 0.464). In our study, Spearman correlation analysis was used and a negative correlation was found between age and PSQI and age and ISI. There is a positive correlation between PSQI and ISI. There are significant differences in tryptophan-kynurenine metabolites in insomnia disease. The data we obtained suggest that tryptophan-kynurein pathway metabolites can be used as biomarkers in the prognosis of the disease. It is thought that understanding the molecules and biochemical mechanisms involved in insomnia will contribute to the development of new effective and safe treatments for the disease.
Our aim in this study is to evaluate the capacity of insomnia patients on the tryptophan-kynurenine pathway. PSQI and ISI scale studies in insomnia patients were included and the relationship between tryptophan-kynurenine metabolites was separated within the scope of the study. The study included 30 patients diagnosed with insomnia between the ages of 18-65 who applied to the Psychiatry outpatient clinic of Selçuk University Faculty of Medicine Hospital and 30 healthy controls. Method verification was provided by conducting a linearity study of the methods installed on the LC-MS/MS (tandem mass spectrometry) device in our routine biochemistry laboratory for the analysis of tryptophan, kynureine, kynurenic acid, 3-OH kynurenine, 3-OH anthranilic acid and quinolic acid levels in the serum samples of the participants. And their levels were measured. The data obtained was carried out using the SPSS 21.0 program. According to the results of our study, PSQI and ISI values were found to be significantly higher in the patient group than in the control group (p=0.001 and p=0.001, respectively). While KYN and KUIN were statistically significantly higher in the patient group than in the control group (p<0.001 and p<0.001, respectively), TRP, KYNA and 3-HK were observed to be lower in the patient group compared to the control group (p=0.001, p<0.001 and p=0.002, respectively). No significant difference was found between the patient and control groups for 3-HAA (p = 0.464). In our study, Spearman correlation analysis was used and a negative correlation was found between age and PSQI and age and ISI. There is a positive correlation between PSQI and ISI. There are significant differences in tryptophan-kynurenine metabolites in insomnia disease. The data we obtained suggest that tryptophan-kynurein pathway metabolites can be used as biomarkers in the prognosis of the disease. It is thought that understanding the molecules and biochemical mechanisms involved in insomnia will contribute to the development of new effective and safe treatments for the disease.
Açıklama
Anahtar Kelimeler
Kinürenin Yolağı, Triptofan, İnsomnia, PUKİ, ISI, Kynurenine Pathway, Tryptophan, Insomnia
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Sakallıoğlu, Z. (2024). İnsomnia hastalarında serum triptofan-kinürenin yolağı metabolit düzeylerinin araştırılması. (Yüksek Lisans Tezi). Selçuk Üniversitesi, Sağlık Bilimleri Enstitüsü, Konya.
